{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004778","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2022-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.644958+00:00","generated_at":"2026-06-26T16:34:53.911603+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ginkgo Bioworks FY2021 revenue $314M (+309% YoY); 2022 guidance $325-340M","bullets":["Full-year 2021 total revenue $314M, up 309% YoY; Foundry revenue $113M (+91%), Biosecurity $201M (exceeded $110M outlook).","Added 31 new Cell Programs in 2021 (+72% YoY); 2022 guidance expects 60 new programs.","Q4 2021 total revenue $148M vs $32M YoY; Adjusted EBITDA $1M vs $(51)M in prior year.","GAAP loss from ops $(1.8)B including $1.7B catch-up stock comp; cash balance >$1.5B.","Announced two tuck-in acquisitions in 2022: Project Beacon (COVID testing) and FGen (strain optimization)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004778","json":"https://secwatch.observer/filing/0000950170-22-004778.json","markdown":"https://secwatch.observer/filing/0000950170-22-004778.md","text":"https://secwatch.observer/filing/0000950170-22-004778.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000095017022004778/0000950170-22-004778-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000095017022004778/dna-20220328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T16:34:53.911603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}